Literature DB >> 19325134

Adverse effects with use of nicotine replacement therapy among quitline clients.

Deborah J Ossip1, Sara M Abrams, Martin C Mahoney, Dana Sall, K Michael Cummings.   

Abstract

INTRODUCTION: Nicotine replacement therapy (NRT) increases quit rates and is increasingly distributed through quitlines, but no systematic data are available on adverse effects and safety among quitline NRT users.
METHODS: Smokers who contacted the New York State Smokers' Quitline and were sent free NRT were followed by phone at 2 weeks (n = 33,690), and a randomly selected subsample was followed at 3 months (n = 1,187). All were asked about their use of NRT and adverse effects. Prevalence and perceived severity (rated mild, moderate, or severe) of selected adverse side effects were assessed. Subjects also were asked about their smoking behavior while using NRT and reasons for discontinuation of NRT.
RESULTS: Among those who reported having used NRT at the 2-week contact, about one in four reported an adverse effect. This rate increased to about 42% among those surveyed at 3 months. The prevalence and specific types of adverse effects reported were consistent with findings from clinical trials of NRT and varied in relationship to the type of NRT used (patch, gum, lozenge). The majority of adverse effects reported were rated as mild, and only 4.4%-5.4% of subjects (across the 2-week and 3-month follow-ups) reported discontinuation of NRT as a result of adverse effects. DISCUSSION: The prevalence and types of adverse effects observed among smokers receiving NRT were as expected with product labeling and support the conclusion that the distribution of over-the-counter NRT through quitlines is safe as long as clients are screened adequately per the labeling instructions.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19325134     DOI: 10.1093/ntr/ntp005

Source DB:  PubMed          Journal:  Nicotine Tob Res        ISSN: 1462-2203            Impact factor:   4.244


  11 in total

1.  Adherence to and reasons for premature discontinuation from stop-smoking medications: data from the ITC Four-Country Survey.

Authors:  James Balmford; Ron Borland; David Hammond; K Michael Cummings
Journal:  Nicotine Tob Res       Date:  2010-12-08       Impact factor: 4.244

2.  Use of a liquid nicotine delivery product to promote smoking cessation.

Authors:  Nicholas Geimer; Carl E Olson; Deborah Baumgarten; James L Kepner; Martin C Mahoney
Journal:  BMC Public Health       Date:  2010-03-24       Impact factor: 3.295

3.  Brain nicotinic acetylcholine receptor availability and response to smoking cessation treatment: a randomized trial.

Authors:  Arthur L Brody; Alexey G Mukhin; Michael S Mamoun; Trinh Luu; Meaghan Neary; Lidia Liang; Jennifer Shieh; Catherine A Sugar; Jed E Rose; Mark A Mandelkern
Journal:  JAMA Psychiatry       Date:  2014-07-01       Impact factor: 21.596

4.  Nicotine gum or patch treatment for smoking cessation and smoking reduction: a multi-centre study in Chinese physicians.

Authors:  Dan Xiao; Nanshan Zhong; Chunxue Bai; Qingyu Xiu; Canmao Xie; Dayi Hu; Yun Mao; Roland Perfekt; Elisabeth Kruse; Qing Li; John Jiangnan Liu; Chen Wang
Journal:  Front Med       Date:  2014-01-23       Impact factor: 4.592

5.  Proactive text messaging (GetReady2Quit) and nicotine replacement therapy to promote smoking cessation among smokers in primary care: A pilot randomized trial protocol.

Authors:  G R Kruse; E Park; J E Haberer; L Abroms; N N Shahid; S E Howard; Y Chang; J S Haas; N A Rigotti
Journal:  Contemp Clin Trials       Date:  2019-03-25       Impact factor: 2.226

6.  Enhancing tobacco quitline effectiveness: identifying a superior pharmacotherapy adjuvant.

Authors:  Stevens S Smith; Paula A Keller; Kate H Kobinsky; Timothy B Baker; David L Fraser; Terry Bush; Brooke Magnusson; Susan M Zbikowski; Timothy A McAfee; Michael C Fiore
Journal:  Nicotine Tob Res       Date:  2012-09-19       Impact factor: 4.244

Review 7.  Adverse effects and tolerability of medications for the treatment of tobacco use and dependence.

Authors:  J Taylor Hays; Jon O Ebbert
Journal:  Drugs       Date:  2010-12-24       Impact factor: 9.546

8.  Efficacy of a nicotine mouth spray in smoking cessation: a randomised, double-blind trial.

Authors:  Philip Tønnesen; Hans Lauri; Roland Perfekt; Karl Mann; Anil Batra
Journal:  Eur Respir J       Date:  2012-02-09       Impact factor: 16.671

9.  Adverse events associated with nicotine replacement therapy (NRT) for smoking cessation. A systematic review and meta-analysis of one hundred and twenty studies involving 177,390 individuals.

Authors:  Edward J Mills; Ping Wu; Ian Lockhart; Kumanan Wilson; Jon O Ebbert
Journal:  Tob Induc Dis       Date:  2010-07-13       Impact factor: 2.600

10.  Effect of offering different levels of support and free nicotine replacement therapy via an English national telephone quitline: randomised controlled trial.

Authors:  Janet Ferguson; Graeme Docherty; Linda Bauld; Sarah Lewis; Paula Lorgelly; Kathleen Anne Boyd; Andy McEwen; Tim Coleman
Journal:  BMJ       Date:  2012-03-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.